Search Follow us


Bionomics’ lead programme is BNC210 for the treatment of anxiety-related disorders. The drug is an orally bioavailable small molecule targeting the α7 nicotinic acetylcholine receptor, which has been implicated in the brain’s response to anxiety. It is currently being tested in a randomized, double-blind Phase IIb clinical study of 192 post-traumatic stress disorder (PTSD) patients, with top-line results expected in H218.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs